Mar 31, 2026 9:15am EDT MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Mar 04, 2026 4:00pm EST MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Mar 02, 2026 10:45pm EST MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
Mar 02, 2026 5:00pm EST MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Feb 24, 2026 8:45am EST MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
Jan 20, 2026 10:15am EST MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
